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Latent Epstein-Barr virus (EBV) infection is associated with several lymphoproliferative disorders, includ-
ing posttransplant lymphoma, Hodgkin’s disease, and Burkitt’s lymphoma, as well as nasopharyngeal carci-
noma (NPC). Twenty-nine microRNAs (miRNAs) have been identified that are transcribed during latent
infection from three clusters in the EBV genome. Two of the three clusters of miRNAs are made from the
BamHI A rightward transcripts (BARTs), a set of alternatively spliced transcripts that are highly abundant in
NPC but have not been shown to produce a detectable protein. This study indicates that while the BART
miRNAs are located in the first four introns of the transcripts, processing of the pre-miRNAs from the primary
transcript occurs prior to completion of the splicing reaction. Additionally, production of the BART miRNAs
correlates with accumulation of a spliced mRNA in which exon 1 is joined directly to exon 3, suggesting that
this form of the transcript may favor production of miRNAs. Sequence variations and processing of pre-
miRNAs to the mature form also may account for various differences in miRNA abundance. Importantly,
residual intronic pieces that result from processing of the pre-miRNAs were detected in the nucleus. The
predicted structures of these pieces suggest there is a bias or temporal pattern to the production of the
individual pre-miRNAs. These findings indicate that multiple factors contribute to the production of the BART
miRNAs and to the apparent differences in abundance between the individual miRNAs of the cluster.
Epstein-Barr virus (EBV) is associated with multiple human
cancers of both lymphoid and epithelial cell origins, including
Burkitt’s lymphoma (BL), Hodgkin’s disease, posttransplant
lymphoma, and nasopharyngeal carcinoma (NPC) (21, 32, 41).
EBV also efficiently transforms B lymphocytes in vitro into
permanent lymphoblastoid cell lines (LCLs) (29, 31). Initial
studies of viral transcription in NPC revealed striking differ-
ences in comparison with transcription in LCLs and BL cell
lines (19, 20, 24, 34). In NPC, the regions that encoded the viral
nuclear proteins EBNAs 2, 3A, 3B, and 3C were not tran-
scribed while the right terminal region including the BamHI A
fragment was abundantly transcribed (21, 34). Subsequent
studies determined that these differences reflected three types
of latent EBV infection. In type III latency, which is charac-
teristic of LCLs, the EBNA2 and EBNA3 proteins were ex-
pressed, while in type II latency found in NPC, these EBNAs
were not expressed (21). In addition in NPC, the BamHI A
RNAs (BamHI A rightward transcripts [BARTs]) were very
abundant and could be detected by Northern blotting (13, 17).
In contrast, in LCLs, the BARTs were expressed at very low
levels, as detected by Northern blotting, but could be detected
by using reverse transcription-PCR (RT-PCR) to detect some
of the specific splices (1, 8, 13, 18, 35). Several open reading
frames (ORFs) have been identified within the differently
spliced BARTs (1, 8, 18, 35, 37). Recombinant proteins rep-
resenting the ORFs have interesting properties; however, the
protein products have not been identified in infected cells (12,
14, 18, 22, 25, 38).
EBV was the first human virus shown to encode microRNAs
(miRNAs) that mapped to the BHRF1 and BART regions of
the genome (30). These miRNAs were initially identified in the
prototype laboratory strain, B95-8, which has a 12-kb deletion
that spans the BART sequences (33). A subsequent study
identified and cloned an additional 14 miRNAs produced from
the BART transcripts in the BC1 cell line, a cell line that is
coinfected with EBV and Kaposi sarcoma herpesvirus (KSHV)
(6). This study analyzed expression of the miRNAs in addi-
tional lymphoid cell lines and the C15 NPC xenograft and
C666.1 NPC cell line. The BART miRNAs were abundant in
C15 and C666.1 and expressed at lower levels in BC1 and the
Jijoye BL cell line (6). Other lymphoid cell lines had barely
detectable expression of some of the miRNAs. This study also
revealed that the BHRF1 miRNAs were actually expressed
from the primary EBNA transcript that is only produced in
lymphocytes with type III latency (6). In addition, a computer
analysis identified nine additional miRNAs within the BART
that are located at various positions between the initial 16
miRNAs (16).
In this study, expression of the BART miRNAs was evalu-
ated in multiple lymphoid and epithelial cell lines. The data
indicate that the levels of expression of the miRNAs are linked
in part to the transcription of the BART mRNA. Interestingly,
stable residual pieces of the intron were detected in the nu-
cleus of cells that express the miRNAs. Characterization of
these residual pieces indicated that the miRNAs are produced
from a large initial transcript prior to splicing and that a
specific spliced form of the transcript favors production of
miRNAs. The specific residual intron pieces remaining after
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the processing of the miRNAs suggest that the individual miRNAs
in the transcript are produced with different efficiencies. These
findings indicate that mRNA abundance and structure regulate
the production of the EBV miRNAs.
MATERIALS AND METHODS
Cell culture and reagents. The EBV-positive BL cell lines Jijoye, Namalwa,
Mutu 1, and Mutu 3, the EBV-negative adenocarcinoma cell line AdAH and the
EBV-positive adenocarcinoma cell line NPC-KT, the EBV-positive and KSHV-
positive PEL line BC1 and the KSHV-positive PEL cell line BCBL1, the EBV-
positive multiple myeloma cell line IM9, and the EBV-positive epithelial cell line
C666.1 were grown at 37°C in RPMI 1640 (Gibco) supplemented with 10% fetal
bovine serum (Sigma) and antibiotics. The gastric carcinoma cell line AGS
infected with the green fluorescent protein (GFP)-tagged Akata EBV strain was
maintained in F-12 medium (Gibco) supplemented with 10% fetal bovine serum
and antibiotics and 500 g/ml G418 (Gibco). NPC tumors C15, C17, and C18
were serially passaged in nude mice and have been described previously (3).
RNA preparations. Total RNA was prepared using TRIzol reagent (Invitro-
gen) from cell pellets or pulverized tumor tissue. Cell fractionations were as
follows: cells were lysed for 10 min on ice in a mixture of 10 mM Tris (pH 7.4),
50 mM KCl, 5 mM MgCl2, and 0.05% NP-40 and then centrifuged at 900  g for
1 min at 4°C. The supernatant was designated “cytosol.” The pellet was washed
in a mixture of 150 mM NaCl, 1.5 mM MgCl2, 10 mM Tris (pH 7.4), and 0.65%
NP-40 and then centrifuged at 900  g for 1 min at 4°C. The resulting pellet was
designated the “nuclear fraction.” RNA was prepared from each fraction using
TRIzol.
Northern blotting. Northern gels to screen for miRNAs were prepared from
precast 15% urea–Tris-borate-EDTA (TBE) gels (Bio-Rad). RNA (5 g) was
mixed with 2 TBE-urea sample buffer (Bio-Rad), heated at 70°C for 4 min,
quick cooled on ice, and then run at 30 mA in 1 TBE. A 72-mer oligonucleotide
and a 20-mer oligonucleotide were used as markers. The gels were stained in
ethidium bromide for visualization and then transferred to Hybond N (GE
Biosciences) at 65 V in 1 TBE for 1 h. After UV cross-linking, the membranes
were hybridized at 37°C with end-labeled antisense oligonucleotides to the
miRNAs or U6 for a control using ExpressHyb solution (Clontech) as directed.
To resolve the mRNA structure and stable intron structure, 10 g of total
RNA, nuclear RNA, or cytosolic RNA was run on 1% agarose gels using
NorthernMax denaturing gel buffer (Ambion), NorthernMax MOPS (morpho-
linepropanesulfonic acid) gel running buffer (Ambion), and RNA Millennium
size markers with formamide (Ambion) as directed. The gels were transferred in
20 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium phosphate) to Hybond
N (GE Biosciences), UV cross-linked, and hybridized with 32P-labeled anti-
sense riboprobes at 68°C in UltraHyb (Ambion) as directed.
Probes. DNA sequences corresponding to the BamHI A coordinates noted in
Table 1 and Fig. 6 were PCR amplified at 40 cycles using Sure Start Taq
(Stratagene), gel purified (Qiaquick gel extraction kit; Qiagen), restriction di-
gested (NEB), and cloned with EcoRI/HindIII into pGEM3Z (Promega). Anti-
sense riboprobes were generated from linearized plasmids using Sp6 polymerase
(Promega) as previously described (35). An antisense riboprobe for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was synthesized from the pTRI-
GAPDH human antisense control template (Ambion). The riboprobes were
purified over G-50 Quick columns (Roche).
Antisense oligonucleotides to the mature miRNAs or U6 were 32P end labeled
with polynucleotide kinase (NEB) and purified over G-25 Quick spin columns
(Roche).
Sequencing. The DNA sequence of the BamHI A region including the miRNAs
was determined at the UNC-CH Genome Analysis Facility using Applied Bio-
systems genetic analyzers with the primers noted in Table 1 from PCR fragments
amplified and gel purified from DNA isolated from the cell lines and xenographs
using the DNeasy kit (Qiagen).
RT-PCR. Total RNA (200 ng) was used as template for RT-PCR using the
primers listed in Table 1 and the Brilliant quantitative RT-PCR core reagent kit
(Stratagene) as directed by the manufacturer. The resulting products were re-
solved on agarose gels, and staining density was quantified using ImageJ. The
resulting product bands were also gel purified (Qiaquick gel extraction kit;
Qiagen) and sequenced.
cDNA cloning. Poly(A) RNA was purified from total RNA from the xenograph
C15 using Oligotex (Qiagen) according to the manufacturer’s instructions. Ten
micrograms of poly(A) RNA was used as a template in an oligo(dT)-primed RT
reaction using OmniScript reverse transcriptase (Qiagen) as directed. This
cDNA was used as a template for full-length cDNA amplification using primers
specific for exon 1 (138353R) and exon 7 (160086L) of the BARTs. PCR was
performed with 5 l of a 1:20 cDNA dilution in a 100-l final volume using the
Expand Long PCR system (Roche) for 30 cycles of denaturing at 94°C for 1 min,
annealing at 62°C for 1 min, and extension at 68°C for 10 min. The resulting PCR
products were size selected on an agarose gel and purified with a Qiaquick gel
extraction kit (Qiagen) as directed. The size-selected fragments (0.3 to 1 kb, 1 to
2 kb, and 2 kb) were kinase treated using polynucleotide kinase (NEB) and
blunt ligated into pGEM3Z. Colonies were screened with an antisense oligonu-
cleotide to exon 1.
5 RACE. Rapid amplification of cDNA ends (RACE) was performed as
follows. To determine the 5 ends of the stable residual pieces resulting from
miRNA processing, BC1 nuclear RNA (200 ng) was primed with intron-specific
primers (primer a) for first-strand cDNA synthesis using Omniscript (Qiagen) as
directed (Table 1). Following cDNA synthesis, the RNA template was subse-
quently digested with RNase H and the cDNA was purified over a Qiaquick
column (Qiagen). The cDNA was poly(A) tailed with terminal transferase
(NEB). The resulting dA-tailed cDNA was diluted 1/5 and used as substrate for
PCR with nested leftward intronic primer b as denoted in Table 1 and an
adapter-dT rightward primer. The PCR was performed under the following
conditions: denaturing at 94°C for 5 min, annealing at 48°C for 2 min, and
extension at 72°C for 40 min, followed by 35 cycles of 94°C for 30 s, 55°C for 30 s,
and 72°C for 2 min. The resulting PCR was run on a 1.5% gel, and the resulting
band was gel purified (Qiagen gel extraction kit) and sequenced.
Nucleotide sequence accession numbers. The EBV coordinates listed corre-
spond to EBV genome sequence AJ507799, in which the Raji sequences have
been inserted into the B95-8-deleted EBV genome (11). The following BamHI
A coordinates of the genomes were sequenced from the cell lines and xenographs
and were deposited in GenBank under the corresponding accession numbers: for
C15 138361 to 140753, 145320 to 148024, and 148181 to 148850, EU828625; for
C17 138381 to 140185, 145931 to 147761, 147821 to 148118, and 148390 to
148850, EU828626; for C18 138384 to 140160, 145931 to 147761, 147831 to
148153, and 148391 to 148850, EU828627; for C666.1 139030 to 140216, 145931
to 147761, 147843 to 148200, and 148378 to 148836, EU828629; for BC1 139036
to 140216 and 145931 to 148850, EU828630; for IM9 138391 to 140170, 145931 to
148030, and 148360 to 148850, EU828628; for Jijoye 139037 to 139300, 139311
to 140216, 145931 to 148307, and 148501 to 148850, EU828631; for Mutu 139041 to
140216, 145931 to 148030, and 148431 to 148850, EU828632; and for Nam 139035
to 140216 and 145931 to 148850, EU828633.
RESULTS
Detection of miRNAs. The BART miRNAs were originally
shown to be expressed at a higher level in epithelial cells,
including the C15 NPC xenograft tumor and NPC cell line
C666.1. Some B cells such as BC1 and Jijoye also expressed the
miRNAs at readily detectable levels (6). To determine if ex-
pression of the miRNAs was related to cell type and to identify
expression of the miRNAs in EBV-infected epithelial and lym-
phoid cells, probes were prepared for the BART1-3p, -3-3p, -4,
-5, -6-3p, -18, -7, -8, -9, -10, -12, -13, and -14 miRNAs and
hybridized to RNA preparations from the infected epithelial
cells AGS-Akata, C18, C17, C666.1, C15, and NPC-KT and
from infected lymphoid cells Jijoye, BC1, IM9, Namalwa,
Mutu 1, and Mutu 3 (Fig. 1). The EBV-negative epithelial cell
line AdAH and the KSHV-positive/EBV-negative lymphoid
cell line BCBL1 were included as negative controls. Loading
was assessed by hybridization to the U6 snRNA. All of the
miRNAs were detected in the C15 NPC tumor, and all but the
BART8 miRNA were detected in the C666.1 NPC cell line.
Lower levels were detected in the BC1 and Jijoye lymphoid
lines. The miRNAs were not detectable in the EBV-infected
NPC-KT or AGS-Akata epithelial cell lines. These findings
indicate that expression of the miRNAs is not characteristic of
a specific cell type. In an interesting study that indicated that
the EBV BART miRNAs could regulate expression of LMP1,
some of the miRNAs were detected in an EBV-infected de-
rivative of the AGS cell line (AGS-BXI) (28). However, the
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AGS cell line analyzed in this study was infected with GFP-
Akata EBV. The absence of miRNAs in the AGS cell line
analyzed here may be due to the difference in the strain of
EBV used to infect the AGS cell line. Surprisingly, BART12
miRNA was readily identified in several lymphoid cell lines,
including IM9, Namalwa, and Mutu, that did not have detect-
able expression of the other miRNAs (Fig. 1).
Structures of the BART RNAs. Previous studies that cloned
large numbers of EBV miRNAs from RNA libraries and the
variable detection of miRNAs by Northern blotting suggest
that there must be additional factors regulating the abundance
of particular miRNAs in a given cell line (Fig. 1) (6, 26).
Considering the variety of mRNAs transcribed from the
BART region, it is possible that the BART miRNA precursors
are produced from a specific transcript(s). It has been difficult
to study NPC, as cell lines that retain the EBV genome cannot
readily be established from the primary tumors and do not
usually grow in nude mice (32). Three NPC xenografts were
established (C15, C17, and C18) that can be passaged in nude
mice (3). The C15 tumor has the same pattern of expression as
EBV-positive NPC primary tumors, while both C17 and C18
do not express most EBV genes (4, 17, 35). One cell line,
C666.1, has been established from NPC that has retained the
EBV genome (9). The BARTs were first identified in the C15
tumor, and multiple RNAs of different sizes can be identified
by Northern blotting (13, 14, 35). Subsequent studies have
identified various structures using cDNA cloning and PCR
amplification (Fig. 2A) (35, 37). The exact structures of the
multiple BARTs of different sizes are not known. Several splic-
ing patterns were detected in size-selected RNAs with the
predominant 4.8-kb RNA containing the spliced form that
would produce the RB2 ORF (Fig. 2B) (35). Two full length
cDNAs were successfully cloned in a cDNA library. One









































Primers for cloning BART cDNAs
138353R GTTGCCATTTTTCAAGCTGCTAAACCACGAGTGG
160086L CTCTCGGAGCTCCTCTATTGGAACTCTGGC
a Primers are numbered at the 5 end according to the EBV genome sequence AJ507799 and extend in the direction indicated (R, rightward; L, leftward). The
EBV-specific nucleotides are shown in boldface in the primers containing restriction sites.
VOL. 82, 2008 REGULATION OF EXPRESSION OF EBV BART miRNAs 9097
exon 1 to exon 3, and contained exons 4, 5, 6, and 7. This is
thought to represent the predominant 4.8-kb mRNA, however,
this RNA only contains approximately 2 kb. The second cDNA
had additional splices within exons 5 and 7 (36). Additional
structures containing exon 1, 1a, 1b, or 2 have been obtained
(7, 11, 35–37). The variation in structure at the 5 end of the
RNA is revealed by hybridization with a probe representing
exon 1 (Fig. 3A). In contrast, fewer RNAs are identified by
hybridization with probes for exon 3 or exon 4, with the major
RNA of approximately 4.8 kb in size detected in the NPC cell
line C666.1, the NPC xenograft C15, the KSHV/EBV-coin-
fected cell line BC1, and the Jijoye BL cell line and with a
larger 7.0-kb RNA detected in BC1 (Fig. 3B). The relative
abundance of the BART RNAs was similar to that previously
shown with readily detectable expression in C666.1, C15,
Jijoye, and BC1 (6). The BARTs were not detectable by North-
ern blotting in two additional NPC xenografts, C17 and C18, or
the EBV-infected gastric cancer cell line AGS-Akata and in
the IM9 and Namalwa lymphoid cell lines.
To further characterize BART expression in C15, C666.1,
BC1, and Jijoye, probes representing the known exons were
hybridized to Northern blots (Fig. 4). The BC1 cell line
uniquely expressed a larger, approximately 7.0-kb RNA.
The 7.0-kb mRNA and 4.8-kb mRNA both hybridized to
probes from exons 1, 2, 3, 4, 5, 6, and 7 but not to exon 1a
or 1b (Fig. 4A). The molecular size of an RNA with these
exons is less than 2.0 kb, and the additional sequences
present in the 7.0-kb RNA in BC1 are unknown. A 4.0-kb
mRNA was detected in C666.1, C15, and BC1 that hybrid-
ized to exons 1, 3, and 4 but not to exon 1a, 1b, or 2 (Fig.
4A). These exons add up to less than 0.8 kb. Previous studies
have identified both the 5 and 3 ends of the BART RNAs,
and the reasons for the disparity between cDNA sequence
and mRNA size have not been determined but may reflect
aberrant gel migration.
In support of the hybridization patterns, two distinct spliced
forms were identified in C15 by cDNA cloning of products that
were amplified using primers specific for exon 1 to exon 7 (Fig.
4B). One cDNA included exons 1, 1a, 2, 3a, 3b, 4, 5a, 6, 7a, and
7b, while a second included exons 1, 3a, 3b, 4, 7a, and 7b. Other
smaller forms spliced directly to exon 7 or included exon 2 or
various forms of exon 3. In all of the clones, 43% spliced from
exon 1 to exon 3, while 18% spliced from exon 1 to exon 2.
These data confirm that the BART mRNAs differ in their
retention of specific exons with variation in the presence of
exons 1a, 1b, 2, and 5. These cDNA sequences suggest that
FIG. 1. Analysis of the BART miRNA expression in the tumor-derived cells and cell lines. Shown is Northern analysis of selected EBV BART
miRNAs in total RNA samples derived from the indicated cell lines and tumors. The BCBL1 cell line served as the negative control, and U6 RNA
served as a loading control.
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some of the mRNAs that splice directly from exon 1 to exon 3
also do not include exons 5 or 6. Thus, the 7.0- and 4.8-kb
mRNAs which contain exon 5 would produce the RB2/A73,
Rk103/RPMS1, and BARF0 ORFs (Fig. 2). The 4.0-kb mRNA
which did not contain exon 5 would not contain any of these
larger ORFs.
To confirm expression of BART RNAs that do not contain
exons 1a, 1b, and 2 and to determine if promoter usage cor-
related with the expression of the BART miRNAs, the RNA
was amplified using primers from the previously identified P1
(bp 138357) and P2 (bp 138081) promoters to exon 3 at bp
149581 (Fig. 5A) (7). Although the BART RNAs were not
detected on Northern blots of C17, C18, IM9, or Namalwa,
BART transcription can be detected by PCR amplification.
Two discrete species initiating from P1 were detected with
variable abundance (Fig. 5B). Discrete bands initiating from
the P2 promoter were not readily detectable (data not shown).
This may reflect greater heterogeneity of transcripts initiating
from P2 (7). The products were excised from the gel and
sequenced. The top 300-bp band contained exons 1, 2, and 3,
while the lower 200-bp fragment contained exons 1 and 3.
Products containing exon 1a or 1b were not obtained. The
fragment containing exons 1, 2, and 3 was detected in all
of the cell lines and was the primary product in IM9, Mutu 3,
Namalwa, and C18. In contrast, the fragment containing exons
1 and 3 and lacking exon 2 was the most abundant form in C15.
Both forms were detected in BC1, C666.1, and Jijoye, with low
levels in IM9, C17, and AGS-Akata (Fig. 5C). The detection of
the 4.0-kb mRNA and the spliced product from exon 1 to exon
3 correlated with those samples in which the expression of the
miRNAs was more abundant: C15, BC1, and C666.1. This
suggests that miRNAs are produced from an mRNA that
splices out a large intron spanning the sequences between
exons 1 and 3.
Stable intron pieces are detectable after miRNA processing.
Stable residual pieces of the intron after Drosha processing have
been identified for the human miR-30 miRNA and for the EBV
BHRF1, -2, and -3 miRNAs, and their detection correlated with
expression of the miRNAs (2, 10, 40). The BART miRNAs are
located between exons 1 and 1a, 1a and 1b, 1b and 2, and 2 and
3 (Fig. 6A). To identify RNA species that could represent residual
introns, RNA blots were hybridized to single-stranded RNA
probes representing exons, specific introns, and pre-miRNAs
(Fig. 6A and Table 1). The probes were prepared by cloning the
sequences indicated in Table 1, and the bp coordinates of the
probes are denoted beneath the boxes marked “probe” in Fig. 6A.
FIG. 2. Structure of the EBV BARTs and the genomic location of the BART miRNAs. (A) Schematic of the promoter, exon, and intron
structures of composite BART cDNAs cloned from the xenograph C15 with the corresponding EBV coordinates (AJ507799) and the location
of the BART miRNAs. The boldface miRNAs were analyzed in this study. The bp sizes of exons and introns are noted. (B) Putative proteins
encoded by the ORFs of the BART cDNAs with the positions of the start and stop codons indicated and the amino acid length of each ORF.
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The introns are designated by the exons that flank them as introns
1-1a, 1a-1b, 1b-2, and 2-3. Several pieces of RNA that hybridized
to specific probes were identified in those cell lines and tumors
that produced the miRNAs (Fig. 6B). An abundant RNA of
approximately 720 nucleotides (nt) was detected with probes rep-
resenting exon 1 and the 5 sequences of intron 1-1a. This RNA
did not hybridize to the pre-miRNA for the BART3 miRNA. The
size of this RNA and its hybridization to exon 1 and intron 1-1a
suggest that it is a residual piece of RNA that would initiate at the
P1 promoter and is not spliced at exon 1 but is processed at 5 end
of the BART3 pre-miRNA (Fig. 6B). A second 1.7-kb RNA was
detected that hybridized to exon 1 and intron 1-1a but also hy-
bridized to the BART3 pre-miRNA, the BART1 pre-miRNA,
and exon 1a but not to the BART6 pre-miRNA. This RNA could
also be a cleavage product of an unspliced transcript through exon
1 to the BART6 pre-miRNA. The detection of two residual
RNAs that terminate at either the BART3 pre-miRNA or the
BART6 pre-miRNA suggests that either the BART6 and
BART3 miRNAs are not both processed simultaneously from the
same individual RNA or the 5 cleavage for the BART6 miRNA
occurs first with subsequent production of the miRNAs between
the BART3 and BART6 miRNAs.
The initial 5 cleavage of BART6 miRNA is also suggested
by the detection of two additional RNA hybridization patterns
FIG. 3. Analysis of the BART mRNA expression and 5 structure in tumor-derived cells and cell lines. (A) Total RNA samples from the
indicated cell lines and tumors were hybridized to an antisense riboprobe to exon 1. GAPDH mRNA expression was used as a loading control.
Size markers are indicated. (B) Total RNA samples were hybridized to antisense riboprobes to exons 3a and 4. GAPDH mRNA expression was
used as a loading control. Size markers are indicated.
FIG. 4. Variation in the BART mRNA structure. (A) Total RNA samples were hybridized to antisense riboprobes to the BamHI A exons.
GAPDH mRNA expression was used as a loading control. Size markers are indicated. (B) Structure of full-length cDNAs cloned from the
xenograph C15.
9100 EDWARDS ET AL. J. VIROL.
(Fig. 6B). One RNA of approximately 680 nt hybridized to the
BART1 pre-miRNA and exon 1a but did not hybridize to the
BART6 pre-miRNA. An additional 5.9-kb RNA was also de-
tected that hybridized to the BART6 pre-miRNA, the probe
representing the sequences at the 3 end of intron 1a-1b, exon
1b, and sequences immediately 5 to the BART18 miRNA but
not to the BART18 pre-miRNA. This suggests that both
BART6 and BART18 miRNAs are processed from the same
intron.
A second large 3.5-kb RNA hybridized to exon 2, BART7
pre-miRNA, BART14 pre-miRNA, and a probe representing
the 3 sequences of intron 2-3a, but not to the BART18 pre-
miRNA or exon 3. This piece would represent an RNA from
which the BART18 miRNA was processed but was contiguous
to exon 3 without processing of BART7, -8, -9, -10, -11, -12,
-13, or -14 miRNA. A small 400-nt RNA that included se-
quences 3 to BART18 miRNA and exon 2 but not the BART7
pre-miRNA would represent the residual piece after process-
ing of the BART18 and BART7 pre-miRNAs.
The production of pre-miRNAs occurs within the nucleus
and the pre-miRNAs are subsequently translocated to the cy-
toplasm. Therefore, the residual pieces formed from process-
ing the BART introns into pre-miRNAs should be present only
within the nucleus. To determine the location of these RNAs,
the BC1 cell line was separated into nuclear and cytoplasmic
fractions (Fig. 7A). Hybridization with the cytoplasmic marker
GAPDH revealed a slight contamination of the nuclear frac-
tion by cytoplasm. The probes intron 1a-1b, exon 1b, and
intron 1b-2 had identified a 5.9-kb residual piece (Fig. 6B).
Hybridization with these probes to RNA from fractionated
cells identified this RNA piece in the total RNA and strongly
within the nuclear fractions (Fig. 7A). The low levels that were
detected in the cytoplasmic fraction are likely due to a small
amount of nuclear RNA that separated with the cytoplasmic
fractions (Fig. 7A). The presence of the 5.9-kb RNA within the
nuclear fraction indicates that these RNAs likely represent
residual RNA after pre-miRNA processing.
To confirm the structures suggested by the hybridizations, 5
RACE was performed. The potential 5 end of the 3.5-kb and
400-nt RNAs was identified using nested primers immediately
5 to the BART7 pre-miRNA and an oligo(dT) adapter primer
(Fig. 7B). The sequence of the amplified fragment terminated
at bp 146021 within the predicted BART18 pre-miRNA.
BART18 was not cloned but was identified by sequence anal-
ysis and predicted to extend to bp 146040.
The detection of these residual pieces that span the se-
quences from P1 to exon 3 and contain exons 1, 1a, 1b, and 2
indicates that the BART miRNAs are produced from an RNA
originating from the P1 promoter prior to any splicing through-
out the region spanning exon 1 through exon 3. The specific
residual pieces also suggest that certain miRNAs are processed
more efficiently from this primary transcript, perhaps account-
ing for the sometimes large differences in expression seen
between individual miRNAs.
Impaired processing in a subset of cell lines and NPC tu-
mors. The Jijoye cell line has abundant BART transcripts
and detectable residual intronic pieces. However, the much
lower expression of the BART miRNAs suggests that there
may be impairment in processing of the pre-miRNAs. To
identify very low levels of expression and identify potential
blocks in processing, AGS-Akata, BC1, and C15 were frac-
tionated into nuclear and cytoplasmic fractions, hybridized
to the BART1-3p, 3-3p,- 4, -5, -7, -9, and -12 miRNAs, and
exposed to film for extended times. The pre-miRNAs for the
BART4 and -7 miRNAs were not detected in C15, BC1,
C666.1, and Jijoye, although the processed miRNAs were
readily detectable (data not shown). This suggests that these
pre-miRNAs are efficiently processed. In contrast, the pre-
miRNAs for the BART1-3p, -3-3p, -5, and -9 miRNAs could
be detected in those samples that expressed the miRNAs.
The variable levels of the pre-miRNAs may reflect differ-
ences in the efficiency of recognition and processing by the
Dicer complex. These pre-miRNAs were also detected in
some samples with low or undetectable miRNA expression,
including AGS-Akata, IM9, and Namalwa (Fig. 1 and data
not shown). The pre-miRNAs for BART1, -5, -9, and -12
were the only pre- or processed miRNAs that were detect-
able in the C17 and C18 tumors. Similar bands were not
FIG. 5. Differential splicing at the 5 end of the mRNAs in tumor-derived cells. (A) Schematic of the promoter and exons of the 5 end of the
BART mRNA with the genomic coordinates noted. (B) RT-PCR analysis using primers specific for P1 and exon 3. The splicing structures of the
products are denoted from sequencing the gel-purified bands.
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detected in fractionated BCBL1 cells with the BART
miRNA probes, indicating that they do not cross-hybridize
to cellular miRNAs. The BART5 pre-miRNA that is the
Drosha product could be detected in all cell lines and tu-
mors, including those that had low or undetectable expres-
sion of the mature miRNAs, such as AGS-Akata, C17, IM9,
and Namalwa (Fig. 8 and data not shown). This finding
indicates that the cell lines that do not express the miRNAs
do have functional Drosha that produces some of the pre-
miRNAs. Hybridization with the U6 snRNA indicated sig-
nificant enrichment in the nuclear fraction with some con-
tamination in the cytoplasmic fraction. However, the
BART5 pre-miRNA was detected in the cytoplasmic frac-
tion but not nuclear fraction of AGS-Akata, C17, IM9, and
Namalwa (Fig. 8). Thus, this detection did not reflect con-
tamination of the cytoplasmic fraction with nuclear RNA as
the pre-miRNAs were not present in the nucleus of these
cell lines. This finding indicates that potential differences in
nuclear export were not responsible for the impaired
miRNA expression.
Sequence variation within the pre-miRNAs. Previous stud-
ies have revealed that sequence variation of a single base
pair can impair or inhibit processing of miRNAs (15). As the
different miRNAs were detected at various levels between
the various samples, the sequences of the pre-miRNAs were
determined and compared to the EBV sequence database
that represents B95-8 sequences with sequences from
the Raji cell line that span the B95-8 deletion. The sequence
differences and the positions of the changes in the pre-
miRNAs are indicated in Fig. 9. The levels of expression of
miRNAs in the samples with sequence changes are com-
pared to those of samples without changes, with U6 included
FIG. 6. Detection of stable intronic RNA structures after miRNA processing. (A) Schematic of the 5 BART region with the genomic
coordinates of the exons, introns, BART pre-miRNAs, and probes used in the Northern analysis. The exon and intron probes are indicated by
boxes with the 5 and 3 coordinates denoted. The pre-miRNA probes are indicated by horizontal lines with the 5 and 3 ends denoted.
(B) Northern analysis and diagrams of the potential stable RNA structures in the tumor-derived cell lines resulting from miRNA processing. Total
RNA was hybridized to antisense riboprobes representing exons, introns, and pre-miRNAs. Size markers are noted. The sizes and projected
endpoints of the stable RNA structures are shown.
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as a loading control (Fig. 9). BC1 had a sequence change
within the BART4 pre-miRNA, and BART4 miRNA was
detectable at levels comparable to those in C666.1 that did
not have this change. In addition, the BART4 miRNA was
the most frequently cloned miRNA from BC1, suggesting
that this sequence change does not affect expression (6).
BC1 and Jijoye had changes in the subsequent miRNA
(BART1), which is 3 to the BART4 miRNA. However, the
BART1-3p miRNA was expressed in BC1 at levels compa-
rable to C15 and C666.1 that did not have this sequence
change. The BART6 miRNA had several deletions within
the proposed hairpin loop, with a deletion of a U in C15,
C666.1, BC1, IM9, and Jijoye and with two additional dele-
tions of U in C666.1. These sequence changes in BART6
pre-miRNA were detected in many of samples and may be
consistent polymorphisms. However, it was difficult to detect
BART6 miRNA, and only three clones of BART6 miRNA
were originally obtained (6). Thus, these changes within the
computer-predicted hairpin possibly impede processing of
this pre-miRNA. The BART7 pre-miRNA had an insert of
an A in C666.1 and a change from A to U in Jijoye but was
expressed at comparable levels in C666.1 and BC1 and at
low levels in Jijoye. In the BART8 pre-miRNA, C666.1 had
two changes of C to U and IM9 shared one of the changes.
BART8 miRNA was difficult to detect in most samples and
was not detected in C666.1. However, all of the other BART
miRNAs were readily detectable in C666.1; therefore, these
changes may affect BART8 miRNA expression (Fig. 1).
Two changes in the BART9 pre-miRNA were detected in
Namalwa, a cell line that does not produce the BART
miRNAs. Interestingly, one of these sequence changes was
the only sequence variation detected within the actual
miRNA. A single change was detected within BART10 in
C666.1; however, C666.1 expressed this miRNA at levels
higher than those in Jijoye or BC1. The BART12 pre-
miRNA had sequence changes in C666.1, Mutu, and Jijoye
but was readily detected in C666.1, C15, and Mutu 3, indi-
cating that these changes did not affect processing. The C17
tumor had multiple changes in the BART13 pre-miRNA and
did not express this miRNA; however, the BART miRNAs could
not be detected in C17 (Fig. 1). These data indicate that with
the exception of the BART6 and BART8 miRNAs, the se-
quence variation in the BART pre-miRNAs analyzed here
apparently does not affect their production. Sequence changes
were also detected in the BART15 miRNA in C15 (T3G, bp
139561) and C17 and C18 (T3C, bp 139545), the BART17
miRNA in C666.1 (C3T, bp 139946), and the BART19
miRNA in C15 and BC1 (G3A, bp 148238) and Namalwa
(C3T, bp 148223), which may affect their processing and ex-
pression; however, these miRNAs were not screened in this
study.
FIG. 7. Detection of the stable intronic RNA in fractionated
BC1 cells and determination of the 5 end of stable RNAs after
miRNA processing. (A) Detection of stable intronic RNA in nu-
clear RNA. The BC1 cell line was separated into nuclear and
cytoplasmic fractions. Northern blots were prepared with total (T),
nuclear (N), and cytoplasmic (C) RNA and probed with antisense
riboprobes representing introns and exon 1b. An antisense ribo-
probe to GAPDH mRNA was used as an indicator of fraction purity
as well as a loading control. Size markers are noted. BCBL1 RNA
was used as a negative control. (B) 5 RACE of the stable 400-nt
and 3.5-kb RNAs identified in Fig. 6B. Leftward intron-specific
primer (a) was used to prime cDNA synthesis. cDNA was tagged
with oligo(dT) and amplified using an oligo(dT) adapter primer and
the nested leftward intron-specific primer (b).
FIG. 8. Impaired processing of the BART5 miRNA. Northern analysis of the BART5 miRNA in total, nuclear, and cytosolic RNA samples
from the indicated tumor-derived cells and cell lines and the detection of the pre-miRNA and the processed miRNA forms. The nuclear U6 RNA
was used as a loading control as well as an indicator of cell fraction integrity.
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DISCUSSION
The data presented in this study reveal that several factors
contribute to production of the EBV BART miRNAs. A major
factor that has been previously shown is that the detection and
apparent abundance of the miRNAs largely reflect the pres-
ence and abundance of the BART RNAs (6). Several promot-
ers have been identified for these RNAs, and the factors that
regulate the transcription of these RNAs have been identified
(7, 11, 35). The P1 promoter has been shown to be the pre-
dominant start site; however, transcripts containing further
upstream sequences have been identified, suggesting multiple
start sites (35). The promoter regions are possibly regulated by
SP1, ets, Jun family members, IRF (interferon regulatory fac-
tor) proteins, c-myc, and C/EBP proteins. Interestingly, one
study that assessed methylation in this region showed that the
sequences downstream of exon 1 were not methylated (11).
This suggested that additional important genetic functions ex-
ist in this region. The transcription through exon 1 and the
downstream region likely reflects that this region is the active
template for the miRNAs (11).
BART miRNA expression did not correlate with cell type in
this study since some epithelial and lymphoid lines had strong
expression, while others had little to no expression. This data
suggests that the regulation of BART miRNA expression is not
specific for cell type or disease state (26). However, the BART
RNAs are not readily detectable in lymphoid cell lines, with
the notable exception of the Jijoye cell line, which has rela-
tively high levels of BART transcription. Although the BART
RNAs are relatively abundant and comparable to those in
C666.1 or BC1, the miRNAs are present at considerably lower
levels in Jijoye. One potentially important difference in the
BART transcripts in the Jijoye cell line is that the 4.0-kb
mRNA that lacked exons 1a, 1b, 5, and 6 was not detected. In
addition, the primary PCR product in Jijoye contained exons 1,
2, and 3. These findings suggest that the miRNAs are poorly
produced in Jijoye as the mRNA lacking exons 1a, 1b, and 2 is
expressed at low levels. Thus, a second level of regulation of
BART miRNA production is the splicing pattern of the
mRNAs. It will be of interest to determine what governs the
processing of the internal 1a, 1b, and 2 exons.
Algorithms have been developed to identify sequences that
contribute to intron/exon retention (39). However, significant
differences in the exon and intron sequences were not detected
between cells that did or did not splice at these exons. Notably,
C15, C666.1, C17, IM9, and C18 have common amino acid
changes in intron 1-1a, and all cell lines studied had similar
amino acid changes in intron 1a-1b. Sporadic changes were
observed in intron 2-3, yet none of the sequence changes cor-
related with differential splicing of the BART exons (data not
shown). Interestingly, a comprehensive study of the KSHV
miRNAs and the structure of the mRNAs that function as the
primary pre-miRNAs indicated that the KSHV miRNAs are
also produced from a large intron produced by alternate splic-
ing (5). One of these mRNAs would be the template for
FIG. 9. Sequence variation within the BART miRNAs (mir-BART) and analysis of miRNA expression. The sequence of the BART pre-
miRNAs is shown with the mature miRNA indicated in italics. Sequence changes are denoted in boldface with the corresponding cell line
indicated. Expression of the miRNA in cell lines with and without sequence changes was determined by Northern blotting and is shown in the top
band. Hybridization to the small nuclear U6 RNA is included as a loading control and is shown in the lower band. Asterisks denote cell lines with
sequence changes.
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kaposin and the miRNAs, while the second would contain the
ORFs for the 71, 72, and 73 proteins. The structure of the
BART RNAs also suggests that one form of the mRNAs con-
tains the intron that is the template for miRNAs while another
contains the large ORFs.
The link between the large intron and the production of
miRNAs is also indicated by the detection of stable, residual
pieces of this intron. These residual RNAs hybridize to exons
1a, 1b, and 2 and to probes representing intron sequences
immediately 5 or 3 to the clusters of miRNAs. The complex-
ity of the RNAs detected on Northern blots probed with exon
1 likely reflects both the complex structure of the mRNAs and
the residual RNAs produced after pre-miRNA cleavage. Im-
portantly, these residual RNAs were detected in the nuclear
fraction, indicating that they are produced by pre-miRNA pro-
cessing. It is possible that different miRNAs are formed from
differently spliced RNAs. Perhaps the smaller intron that is
produced from an RNA containing exon 1a, 1b, or 2 is a
template for some of the miRNAs. This could explain why
IM9, which only contained RNA with exon 2, only produced
BART12 miRNA.
Considering the complexity of the RNAs detected with mul-
tiple probes, it is likely that other residual pieces are produced
that were not identified. However, the retention of several
pre-miRNAs but not others within these pieces may indicate
that some of the miRNAs are preferentially processed. The
BART18 pre-miRNA probe did not detect any residual RNAs,
although RNAs were detected that hybridized to probes im-
mediately 5 and 3 to this RNA. This suggests that this pre-
miRNA is efficiently processed. The processing at the 3 end of
the BART18 pre-miRNA was confirmed by 5 RACE for two
of the residual fragments. Preferential processing is also sug-
gested by the residual fragments that contain the BART6 pre-
miRNA. Two RNAs were detected that would represent the
pieces after cleavage at the 5 end of the BART6 pre-miRNA.
One included the BART1 pre-miRNA through BART6, and
the second included exon 1 to BART6. The ability to detect
these RNAs, which are likely the most abundant of the residual
pieces, may be due to preferential processing of some pre-
miRNAs or may indicate a temporal sequence of cleavage.
The detection of exon 1 sequences in two of the RNAs
suggests that the miRNAs are produced from the intron prior
to processing of the exons. Studies of cellular miRNA synthesis
have suggested that intronic miRNAs are processed from
the intron prior to splicing (23). This would require that the
miRNAs are produced after the exon borders are tethered
together but are not cleaved. The residual pieces detected in
this study indicate that either the intron lariat has been cleaved
at the 3 end but not the 5 end of the intron or that the
primary pre-miRNA has an additional 5 splice that produces
the intron containing the identified exon 1 (42).
Another potential regulatory level for miRNA synthesis is
the Dicer processing to produce the miRNAs. With the excep-
tion of miRNA 5, detection of the pre-miRNAs was variable.
The pre-miRNAs for BART1, -3, and -5 could be detected in
cell lines that produced the miRNAs, while the precursors for
BART4 and -7 were not detected. This finding suggests the
Drosha products vary in their efficiency of processing by Dicer.
In cell lines that did not have detectable mature miRNAs, the
pre-miRNAs could be detected for some but not all of the
miRNAs. In particular, the pre-miRNAs for BART5, -9, and
-12 miRNAs were detected in C17, C18, and IM9. Of these,
only the processed BART12 miRNA could be detected in IM9.
Thus, there is some regulation of Dicer activity preventing the
production of mature miRNAs in these cases. However, in all
cases, the pre-miRNAs were detectable in the cytoplasmic
fractions, indicating that transport to the cytoplasm is not im-
paired or regulated distinctly in cell lines without miRNAs.
The further study of viral miRNAs is likely to increase our
understanding of factors that regulate their synthesis. The gen-
esis of cellular miRNAs is complicated by uncertainties in
coding and noncoding regions and multiple mRNAs whose
structures are not known. Many potential cellular miRNAs
have been predicted by sequence, and their positions with
regard to known protein coding sequences have been deter-
mined (27). These analyses have revealed that approximately
25% of cellular miRNAs are within the introns of known cod-
ing mRNAs, and half of these are within introns greater than
5 kb. The large BART intron that is the template for the
miRNAs is approximately 11 kb. Splicing at exon 1a or 1b
would result in introns approximately 1 kb, while splicing at
exon 2 would produce a 3-kb intron. This larger intron could
serve at the template for the BART7 to -14 miRNAs. In the
lymphoid cell lines IM9, Namalwa, and Mutu, where the pre-
dominant form was spliced to include exon 2, only BART12
miRNA, which lies in the middle of this intron, was identified.
Thus, the production of miRNAs in these cell lines may be
impeded by the splicing reaction at exon 2.
The data presented here indicate several factors contribute
to expression of the BART miRNAs. These include the abun-
dance of the BART RNAs and specific splicing patterns. The
residual RNAs produced by BART pre-miRNA processing
have been partially characterized here by their hybridization to
exons and introns. It will be of interest to further identify the
exact 5 and 3 ends of these RNAs and other residual RNAs.
The further study of these RNAs is likely to provide new
information on the temporal production of the pre-miRNAs
and other factors that contribute to their biogenesis.
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